Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.
Metastatic Breast Cancer
DRUG: Pyrotinib Maleate combine with Docetaxel
Objective Response Rate, Ratio of CR and PR in all subjects, from enrollment to progression or death (for any reason), assessed up to 100 months
PFS, Progression-Free Survival, from enrollment to progression or death (for any reason),assessed up to 100 months|DoR, Duration of Response, The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months|Clinical Benefit Rate, Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects, from enrollment to progression or death (for any reason),assessed up to 100 months|OS, Overall Survival, from enrollment to death (for any reason).assessed up to 100 months
adverse event, Adverse events are described in terms of CTC AE 5.0, from enrollment to 30 days after the last dose administrate
A multi-center, one-arm, open label design study,which is planned to enroll 79 patients with HER2-positive metastatic breast cancer receiving first-line treatment with pyrotinib and docetaxel. The main purpose of this study was to observe the efficacy and safety of first-line treatment with pyrrolidine and docetaxel for HER2-positive metastatic breast cancer.